Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022

Background: In 2022, a global monkeypox virus (MPXV) clade II epidemic occurred mainly among men who have sex with men. Until early 1980s, European smallpox vaccination programmes were part of worldwide smallpox eradication efforts. Having received smallpox vaccine > 20 years ago may provide some...

ver descrição completa

Detalhes bibliográficos
Autores: Colombe, Soledad, Funke, Silvia, Koch, Anders, Haverkate, Manon, Monge Corella, Susana, Barret, Anne-Sophie, Vaughan, Aisling, Hahné, Susan, van Ewijk, Catharina, Emborg, Hanne-Dorthe, von Schreeb, Sebastian, Díaz, Asunción, Olmedo, Carmen, Zanetti, Laura, Levy-Bruhl, Daniel, de Sousa, Luis Alves, Hagan, José, Nicolay, Nathalie, Pebody, Richard
Tipo de documento: artigo
Data de publicação:2024
País:España
Recursos:Instituto de Salud Carlos III (ISCIII)
Repositório:Repisalud
Idioma:inglês
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/25372
Acesso em linha:https://hdl.handle.net/20.500.12105/25372
Access Level:Acceso aberto
Palavra-chave:Europe
Childhood smallpox vaccination
Monkeypox
mpox
Screening method
Vaccine effectiveness
Adult
Denmark
France
Homosexuality, Male
Humans
Immunization Programs
Male
Mpox (monkeypox)
Netherlands
Smallpox
Spain
Vaccination Coverage
Vaccination
Vaccine Efficacy
id ES_5bb46305e68d2a5603adf9396c60c9cd
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/25372
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022Colombe, SoledadFunke, SilviaKoch, AndersHaverkate, ManonMonge Corella, SusanaBarret, Anne-SophieVaughan, AislingHahné, Susanvan Ewijk, CatharinaEmborg, Hanne-Dorthevon Schreeb, SebastianDíaz, AsunciónOlmedo, CarmenZanetti, LauraLevy-Bruhl, Danielde Sousa, Luis AlvesHagan, JoséNicolay, NathaliePebody, RichardEuropeChildhood smallpox vaccinationMonkeypoxmpoxScreening methodVaccine effectivenessAdultDenmarkEuropeFranceHomosexuality, MaleHumansImmunization ProgramsMaleMpox (monkeypox)NetherlandsSmallpoxSpainVaccination CoverageVaccinationVaccine EfficacyBackground: In 2022, a global monkeypox virus (MPXV) clade II epidemic occurred mainly among men who have sex with men. Until early 1980s, European smallpox vaccination programmes were part of worldwide smallpox eradication efforts. Having received smallpox vaccine > 20 years ago may provide some cross-protection against MPXV. Aim: To assess the effectiveness of historical smallpox vaccination against laboratory-confirmed mpox in 2022 in Europe.MethodsEuropean countries with sufficient data on case vaccination status and historical smallpox vaccination coverage were included. We selected mpox cases born in these countries during the height of the national smallpox vaccination campaigns (latest 1971), male, with date of onset before 1 August 2022. We estimated vaccine effectiveness (VE) and corresponding 95% CI for each country using logistic regression as per the Farrington screening method. We calculated a pooled estimate using a random effects model. Results: In Denmark, France, the Netherlands and Spain, historical smallpox vaccination coverage was high (80-90%) until the end of the 1960s. VE estimates varied widely (40-80%, I2 = 82%), possibly reflecting different booster strategies. The pooled VE estimate was 70% (95% CI: 23-89%). Conclusion: Our findings suggest residual cross-protection by historical smallpox vaccination against mpox caused by MPXV clade II in men with high uncertainty and heterogeneity. Individuals at high-risk of exposure should be offered mpox vaccination, following national recommendations, regardless of prior smallpox vaccine history, until further evidence becomes available. There is an urgent need to conduct similar studies in sub-Saharan countries currently affected by the MPXV clade I outbreak. the excitatory neurons cluster (Done from ReviGO).European Centre for Disease Prevention and Control (ECDC)20242024-10-2920242024-08-0120242024-08-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12105/25372reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/253722026-06-12T12:43:37Z
dc.title.none.fl_str_mv Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022
title Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022
spellingShingle Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022
Colombe, Soledad
Europe
Childhood smallpox vaccination
Monkeypox
mpox
Screening method
Vaccine effectiveness
Adult
Denmark
Europe
France
Homosexuality, Male
Humans
Immunization Programs
Male
Mpox (monkeypox)
Netherlands
Smallpox
Spain
Vaccination Coverage
Vaccination
Vaccine Efficacy
title_short Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022
title_full Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022
title_fullStr Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022
title_full_unstemmed Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022
title_sort Effectiveness of historical smallpox vaccination against mpox clade II in men in Denmark, France, the Netherlands and Spain, 2022
dc.creator.none.fl_str_mv Colombe, Soledad
Funke, Silvia
Koch, Anders
Haverkate, Manon
Monge Corella, Susana
Barret, Anne-Sophie
Vaughan, Aisling
Hahné, Susan
van Ewijk, Catharina
Emborg, Hanne-Dorthe
von Schreeb, Sebastian
Díaz, Asunción
Olmedo, Carmen
Zanetti, Laura
Levy-Bruhl, Daniel
de Sousa, Luis Alves
Hagan, José
Nicolay, Nathalie
Pebody, Richard
author Colombe, Soledad
author_facet Colombe, Soledad
Funke, Silvia
Koch, Anders
Haverkate, Manon
Monge Corella, Susana
Barret, Anne-Sophie
Vaughan, Aisling
Hahné, Susan
van Ewijk, Catharina
Emborg, Hanne-Dorthe
von Schreeb, Sebastian
Díaz, Asunción
Olmedo, Carmen
Zanetti, Laura
Levy-Bruhl, Daniel
de Sousa, Luis Alves
Hagan, José
Nicolay, Nathalie
Pebody, Richard
author_role author
author2 Funke, Silvia
Koch, Anders
Haverkate, Manon
Monge Corella, Susana
Barret, Anne-Sophie
Vaughan, Aisling
Hahné, Susan
van Ewijk, Catharina
Emborg, Hanne-Dorthe
von Schreeb, Sebastian
Díaz, Asunción
Olmedo, Carmen
Zanetti, Laura
Levy-Bruhl, Daniel
de Sousa, Luis Alves
Hagan, José
Nicolay, Nathalie
Pebody, Richard
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Europe
Childhood smallpox vaccination
Monkeypox
mpox
Screening method
Vaccine effectiveness
Adult
Denmark
Europe
France
Homosexuality, Male
Humans
Immunization Programs
Male
Mpox (monkeypox)
Netherlands
Smallpox
Spain
Vaccination Coverage
Vaccination
Vaccine Efficacy
topic Europe
Childhood smallpox vaccination
Monkeypox
mpox
Screening method
Vaccine effectiveness
Adult
Denmark
Europe
France
Homosexuality, Male
Humans
Immunization Programs
Male
Mpox (monkeypox)
Netherlands
Smallpox
Spain
Vaccination Coverage
Vaccination
Vaccine Efficacy
description Background: In 2022, a global monkeypox virus (MPXV) clade II epidemic occurred mainly among men who have sex with men. Until early 1980s, European smallpox vaccination programmes were part of worldwide smallpox eradication efforts. Having received smallpox vaccine > 20 years ago may provide some cross-protection against MPXV. Aim: To assess the effectiveness of historical smallpox vaccination against laboratory-confirmed mpox in 2022 in Europe.MethodsEuropean countries with sufficient data on case vaccination status and historical smallpox vaccination coverage were included. We selected mpox cases born in these countries during the height of the national smallpox vaccination campaigns (latest 1971), male, with date of onset before 1 August 2022. We estimated vaccine effectiveness (VE) and corresponding 95% CI for each country using logistic regression as per the Farrington screening method. We calculated a pooled estimate using a random effects model. Results: In Denmark, France, the Netherlands and Spain, historical smallpox vaccination coverage was high (80-90%) until the end of the 1960s. VE estimates varied widely (40-80%, I2 = 82%), possibly reflecting different booster strategies. The pooled VE estimate was 70% (95% CI: 23-89%). Conclusion: Our findings suggest residual cross-protection by historical smallpox vaccination against mpox caused by MPXV clade II in men with high uncertainty and heterogeneity. Individuals at high-risk of exposure should be offered mpox vaccination, following national recommendations, regardless of prior smallpox vaccine history, until further evidence becomes available. There is an urgent need to conduct similar studies in sub-Saharan countries currently affected by the MPXV clade I outbreak. the excitatory neurons cluster (Done from ReviGO).
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-10-29
2024
2024-08-01
2024
2024-08-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/25372
url https://hdl.handle.net/20.500.12105/25372
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv European Centre for Disease Prevention and Control (ECDC)
publisher.none.fl_str_mv European Centre for Disease Prevention and Control (ECDC)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408822062219264
score 15,198674

Registros relacionados